HC Wainwright Reiterates $3.00 Price Target for Protalix Biotherapeutics (NYSEAMERICAN:PLX)
Protalix Biotherapeutics (NYSEAMERICAN:PLX) received a $3.00 price target from HC Wainwright in a report issued on Friday, TipRanks reports. The firm currently has a “buy” rating on the stock.
Separately, Zacks Investment Research upgraded Protalix Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, October 15th.
Shares of PLX stock traded down $0.03 during mid-day trading on Friday, hitting $0.29. The stock had a trading volume of 3,993,193 shares, compared to its average volume of 556,246. Protalix Biotherapeutics has a 12-month low of $0.17 and a 12-month high of $0.60.
A hedge fund recently raised its stake in Protalix Biotherapeutics stock. Renaissance Technologies LLC increased its stake in shares of Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) by 7.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,326,528 shares of the company’s stock after purchasing an additional 308,823 shares during the quarter. Renaissance Technologies LLC owned approximately 2.92% of Protalix Biotherapeutics worth $2,029,000 as of its most recent SEC filing.
About Protalix Biotherapeutics
Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease.
Featured Story: What is a blue-chip stock?
Receive News & Ratings for Protalix Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.